In march 2011, Bioporto signed the first non-exclusive license agreement for access to the NGAL cut-off patent.
The deal was made with US based Instrumentation Laboratory (part of the Werfen Group), and paid an initial 250.000€, rising to 2.000.000€ in milestones. The deal also holds a 5,5% royalty for Bioporto.
More important though, entering into an agrement with IL is like a “stamp of approval” from a major player in the medical sector, and a most welcome allied.
today they announced another type of Agreement, basically for a Homogenous Test (as opposed to the heterogenous test under developement by Instrumentation Lab). The NGALtest will be part of a immunoassay marketed by the Wiener Group of Argentina under their own label …